To hear about similar clinical trials, please enter your email below
Trial Title:
Blood Flow MRI for Monitoring Brain Tumors
NCT ID:
NCT01538264
Condition:
Brain Tumors
Conditions: Official terms:
Brain Neoplasms
Study type:
Observational
Overall status:
Active, not recruiting
Study design:
Time perspective:
Cross-Sectional
Summary:
The investigators are studying the use of an advanced magnetic resonance imaging (MRI)
technique for measuring blood flow into brain tumors. This technique does not use
radioactive tracers, and it can provide high quality images that can be obtained in a
standard MRI scanner.
Detailed description:
Our goals are:
1. To compare the blood flow measured with this technique with measures of tumor blood
vessel density in pieces of the tumor surgically removed as a normal part of
clinical treatment. This will confirm a relationship between the imaging
measurements and the microscopic characteristics of tumors.
2. To compare the blood flow in tumors before therapy with the concentration of
choline, an indicator of cell proliferation. This choline concentration can be
measured with another MRI technique. This information will demonstrate the
relationship between cell proliferation and blood supply and will also determine
whether the choline measurement adds additional information that is clinically
necessary.
3. To determine the reproducibility of blood flow measurements in tumors. This is
necessary to better understand the sensitivity of the technique to changes in flow
caused by a treatment or changes in tumor vascularity.
4. To monitor changes in blood flow after initial treatment. Since sometimes tumors can
reappear, the repeated measures will help determine how useful this new imaging
technique is at detecting such recurring tumors.
Criteria for eligibility:
Study pop:
All subjects will be brain tumor patients recruited through the Brain Tumor Center at the
Beth Israel Deaconess Medical Center.
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- diagnosed with or are suspected of having a glioma
Exclusion Criteria:
- contraindications to MRI which may include the following
1. Pacemaker
2. MRI incompatible metal implant
3. Recently implanted vascular clip
4. History of claustrophobia
5. Metal fragment within the eye
Subjects who have received nonstandard therapy may be excluded if the therapy might alter
tumor blood flow or other imaging characteristic.
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Beth Israel Deaconess Medical Center
Address:
City:
Boston
Zip:
02215
Country:
United States
Start date:
June 2006
Completion date:
December 31, 2025
Lead sponsor:
Agency:
Beth Israel Deaconess Medical Center
Agency class:
Other
Collaborator:
Agency:
National Cancer Institute (NCI)
Agency class:
NIH
Source:
Beth Israel Deaconess Medical Center
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT01538264
